A pharmaceutical composition in the form of a solution comprising water insoluble therapeutically active ingredient and a close structural analog of the water insoluble active ingredient, one or more pharmaceutically acceptable excipients and one or more water miscible solvents wherein the water insoluble active ing...

The present invention relates to an improved process for the preparation of unilamellar liposomal composition of a polyene antibiotic drug that is stable and show better purity profile. The present inventors when tried preparing liposomal composition of polyene antibiotic drug by following processes known in the pri...

The present invention relates to novel carbamate intermediate, process for its preparation and process for its conversion into 3-[(1R,2R)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol, tapentadol and its pharmaceutical!}" acceptable salts.

The present invention relates to a method of loading an ionizable drug having a group selected from or pharmaceutically acceptable salts thereof into a liposome and the liposomal composition of drug produced therewith.

The present invention relates to crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6a,9a-difluoro-17a-(furan-2-yl)carbonyloxy-11ß-hydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17ß-carbothioate, an anti-inflammatory and anti-allergic glucocorticoid compound.

The present invention describes a device suitable for dispensing multiple doses of a liquid medicament, the device comprising a) a container having a liquid medicament therein, comprising at least one collapsible wall (3) b) a rotating plunger (7) connected to a push button (8) and c) locking means wherein upon...

The present invention relates to a method of preparing a nanoparticulate topical composition of a water soluble, water-susceptible active ingredient or its pharmaceutically acceptable salt, the method comprising steps of milling the water soluble, water-susceptible active ingredient or its salt, a wetting agent and ...

The present invention relates to a nanoparticulate topical composition comprising (i) nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm, (ii) one or more wetting ag...

An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are adminis...

The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic...

The present invention relates to a viscoelastic gel comprising therapeutically effective amount of liraglutide, wherein the gel does not have a block or a graft copolymer, and wherein the gel is characterized by yield value from 200Pa to 3000 Pa and flow point from 300Pa to 3500Pa. The invention also provides method...

The present invention relates to metered dose inhaler devices for the administration of medicament to patients for inhalation therapy. Particularly, it discloses a metered dose inhaler device for improving medicament compliance by patients.

The present invention relates to novel N-acylaminoheteroarylethynyl hydrazides as tyrosine kinase inhibitors, process of preparation thereof, and use of the compounds for preparation of pharmaceutical compositions in the therapeutic treatment of disorders related to tyrosine kinases in humans. ...

The present invention relates to an aqueous suspension comprising (a) reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 9...

The present invention provides a stable ready-to-use solution comprising therapeutically effective amounts of glucagon and pharmaceutically acceptable vehicle.

An ophthalmic solution comprising therapeutically effective amount of a prostaglandin or its analog alone or in combination with other antiglaucoma agents and water soluble excipient(s) dissolved in a pharmaceutically acceptable vehicle, wherein the solution is free of a surfactant.

An immediate-release, abuse-resistant solid dosage form comprising melt extrudates of a mixture of: • hydrocodone or its pharmaceutically acceptable salt, • release inhibiting agent comprising one or more reverse enteric polymer and one or more alkalizer and • one or more stabilizers.

A multi-particulate pharmaceutical composition suitable for administration in a sprinkle dosage form said particles being less than 2 mm in diameter and comprising a) inert core particles b) an inner layer surrounding said inert core particles, said layer comprising atorvastatin calcium, methyl methacrylate butyl ...

The present invention relates to nano-resin particles that are suitable for pharmaceutical use and their use in the pharmaceutical field. The present invention provides nano-sized resin particles having a particle size distribution characterized in that D90 value is between 200 nanometers to 900 nanometer and D10 va...

(1) salmeterol xinafoate having m The dry powder inhalation composition comprising ean particle size in ran of 2.0 µ - 6 µ, microns and a tapped density in the range of 0.20 g.cm-3 to 0.45 g.cm-3  and (2) optionally, one or more other active ingredients and pharmaceutically acceptable carrier. ...

A stable multi-particulate pharmaceutical composition comprising pellets filled in capsule, sachet or pouch, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts, one or more osmotic release modifiers and one or more stabilizers.

An oral pharmaceutical composition comprising tizanidine or pharmaceutically acceptable salts thereof, as the sole active ingredient in admixture with a release modifying agent wherein the release modifying agent comprises atleast one release modifying hydrophobic non-polymeric material, and wherein the bioavailabil...

The present invention provides novel N-aryl containing fused heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/ degraders and process for their preparation.

The present invention relates to a composition comprising particles wherein said particles comprise Poly(lactide co glycolide) polymer therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof and a hydrophilic particle size modulating agent wherein the composition is free of adde...

The present invention provides an ophthalmic solution comprising therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of quaternary ammonium compound and polyethoxylated castor oil, in an aqueous vehicl...

The present invention relates to novel amidoheteroaryl aroyl hydrazide ethynes as tyrosine kinase inhibitors process of preparation thereof and use of the compounds for preparation of pharmaceutical compositions in the therapeutic treatment of disorders related to tyrosine kinases in humans.

The present invention relates to an applicator for administering an adjustable preset dose of a medicament comprising: a syringe enclosure; a syringe; a plunger rod with ratchets; a dose setting cap with snaps to snap on the ratchets on the plunger rod for adjusting and setting the medicament dose to be administered...

The present invention relates to coated capsules comprising • capsule comprising therapeutically active ingredient and pharmaceuticallyacceptable carrier and • the coating composition comprising a hydrophobic polymer and a hydrophilic substance; wherein the said coating composition is applied directly to the ...

The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more drugs, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or...

The present invention discloses a novel process of preparation of doxorubicin liposomal suspension having entrapment efficiency greater than or equal to 95%.

A substantially porous, micro-particle comprising therapeutically effective amounts of tretinoin and ethyl cellulose.

The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amounts of N-(2-pyrazine) carbonyl-L-phenylalanine-L-leucine boronic acid or its salts or its derivatives and tromethamine wherein the composition is stable.

A compound of formula I (R)m RP" X_ a-_ (CH2) t Z- /-(CH2)Pl (C H2)p2 1 s 0 R N (CH2)n CN (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof. wherein "a"-is selected from the group consisting of substituted or unsubs...

An ophthalmic composition comprising therapeutically effective amount of a beta-blocker and a pharmaceutically acceptable polymer consisting of a combination of hydroxypropylmethylcellulose and polyvinylpyrrolidone, wherein the composition is a clear aqueous solution with a viscosity greater than 15 cps. ...

NOVEL PRODRUGS

The present invention relates to an injectable pharmaceutical composition comprising antipsychotic agents having basic groups.

The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a non-aqueous solvent and water, said nanoparticles comprising one or more therapeutically active ingerdient wherein at least one therapeutically active ingredient is a taxan...

The present invention provides a controlled release dosage form comprising a mixture of betahistine or its pharmaceutically acceptable salt complexed with ion exchange resin with one or more gel forming polymer. Further, in preferred aspect, the present invention provides a controlled release solid dosage form c...

The present invention relates to novel cysteinyl leukotriene (specifically LTD4) antagonists, mainly to quinolin, quinoxaline or benz[c]thiazole derivatives represented by the general formula (I), or the pharmaceutically acceptable salt thereof, process of preparation thereof, and to the use of the compounds in ...

A compound of formula (I), or pharmaceutically acceptable salt thereof, as renin inhibitor, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of cardiovascular disorders related to hypertension, in warm-blooded animals....

formula I The present invention relates to methods of treatment of inflammatory conditions using  S-[4-(3-fluoro-3-methylbutyryloxy)-but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl)carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate (compound of formula I), a novel anti-inflammatory compound of t...

The present invention relates to a composition comprising particles, wherein said particles comprise Poly(lactide-co-glycolide) polymer, therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof and a hydrophilic particle size modulating agent, wherein, the composition is free of ...

The present invention provides an oral controlled release tablet; said tablet comprising:a core comprising an upper compressed layer comprising a swelling ag£"t, and o a lower compressed layer comprising at least one therapeutically active ingredient, and pharmaceutically acceptable excipient wherein at least one ex...

The present invention provides novel heterocyclic compounds as anticancer agents especially as estrogen receptor (ER) antagonists/ degraders and process for their preparation.

An oral drug delivery system comprising a coated tablet having one or more surfaces, the coated tablet further comprising:a core comprising an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable ...

The present invention relates to an ophthalmic solution of bimatoprost comprising 0.005 % to 0.015 % weight by volume of bimatoprost or its pharmaceutically acceptable salt, a biguanide compound and an acylated amino acid wherein the solution is free of benzalkonium chloride. The ophthalmic solution of bimatoprost ...

TREATMENT FOR SYNUCLEINOPATHIES A method of treating or preventing synucleinopathies in a human subject comprising administering a therapeutically effective amount of a compound of Formula 1, N NH NH Cl CH3 H3C O O Formula 1 or its pharmaceutically acceptable salt.

OPHTHALMIC SOLUTION OF DIFLUPREDNATE The present invention provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii....

The present invention relates an improved process for the preparation of an aqueous ophthalmic solution of difluprednate or pharmaceutically acceptable salts thereof. The present invention further relates to an aqueous ophthalmic solution of difluprednate or pharmaceutically acceptable salts thereof, prepared by the...

An oral solid dosage form comprising a mixture of compound of formula I Formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

This invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof (wherein X, Y, Z and n are defined herein). These compounds are useful in the treatment of diseases mediated by topoisomerase I enzyme such as cancers. The present invention also provides processes for the preparation of co...

A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharm...

The present invention relates to novel hydrazino compounds of Formula I as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in...

An oral, solid dosage form comprising a mixture of compound of formula I Formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion. To The Controller of Patents, Patent Office, Mumbai – 400037 ...

An abuse deterrent oral solid dosage form comprising: • an inner portion comprising a drug susceptible to abuse and a pH dependent polymer soluble in acidic medium • an outer portion, wherein the portion is devoid of drug susceptible to abuse and comprises an immediate release form of alkalizer and a sustained re...

An oral solid dosage form comprising a mixture of compound of formula I Formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion. To The Controller of Patents, Patent Office, Mumbai – 400037 ...

The invention relates to a method of treating or preventing Parkinson"s disease in a subject comprising administering a compound of Formula I wherein R1 is -NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring wherein the rin...

The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized p...

The invention relates to a method of treating or preventing Parkinson"s disease in a subject comprising administering a compound of Formula I wherein R1 is -NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring wherein the rin...

ABSTRACT STABLE EXTENDED RELEASE COMPOSITION OF GABAPENTIN The present disclosure relates to a stable biphasic extended release gastro-retentive composition comprising a higher load of gabapentin or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipient. The composition pro...

The present disclosure relates to the c-Abl inhibitor vodobatinib, or a pharmaceutically acceptable salt thereof, for use in treating, delaying, inhibiting, or suppressing the progression of neurodegenerative diseases, preferably early stage Parkinson's disease, in a subject.

The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized p...

The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of Formula 1 has been shown to be efficacious safe and tolera...

The present invention generally relates to Ligand-drug conjugates of the Formula I: or pharmaceutically acceptable salts, stereoisomers or isotopes thereof. The invention further relates to the use of the compound of Formula I, for the treatment of cancer.